Cubist Systematic Strategies, LLC Provention Bio, Inc. Transaction History

Cubist Systematic Strategies, LLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$6.7 - $24.21 $1.1 Million - $3.99 Million	-164,859 Reduced 71.86%	64,550 $1.56 Million
Q4 2022 Feb 14, 2023	BUY	$4.52 - $10.57 $594,303 - $1.39 Million	131,483 Added 134.27%	229,409 $2.42 Million
Q3 2022 Nov 14, 2022	BUY	$3.43 - $5.62 $7,978 - $13,072	2,326 Added 2.43%	97,926 $441,000
Q2 2022 Aug 15, 2022	BUY	$3.65 - $7.3 $282,823 - $565,647	77,486 Added 427.77%	95,600 $382,000
Q1 2022 May 16, 2022	SELL	$3.4 - $7.88 $2,475 - $5,736	-728 Reduced 3.86%	18,114 $133,000
Q4 2021 Feb 14, 2022	BUY	$5.59 - $7.39 $44 - $59	8 Added 0.04%	18,842 $106,000
Q3 2021 Nov 15, 2021	SELL	$5.66 - $8.33 $30,558 - $44,973	-5,399 Reduced 22.28%	18,834 $121,000
Q2 2021 Aug 16, 2021	SELL	$6.71 - $11.04 $429,158 - $706,096	-63,958 Reduced 72.52%	24,233 $204,000
Q1 2021 May 17, 2021	BUY	$10.12 - $19.45 $892,492 - $1.72 Million	88,191 New	88,191 $926,000
Q4 2020 Feb 16, 2021	SELL	$11.79 - $18.94 $232,569 - $373,610	-19,726 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$10.34 - $15.2 $351,456 - $516,648	-33,990 Reduced 63.28%	19,726 $253,000
Q2 2020 Aug 14, 2020	BUY	$7.81 - $17.0 $215,048 - $468,095	27,535 Added 105.17%	53,716 $758,000
Q1 2020 May 15, 2020	BUY	$5.42 - $17.75 $141,901 - $464,712	26,181 New	26,181 $241,000
Q2 2019 Aug 14, 2019	SELL	$2.3 - $13.79 $1,150 - $6,895	-500 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$1.97 - $2.57 $1,871 - $2,441	-950 Reduced 65.52%	500 $1,000
Q4 2018 Feb 14, 2019	BUY	$1.73 - $4.0 $2,508 - $5,800	1,450 New	1,450 $3,000

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.